Levobupivacaine Fresenius Kabi Deutschland (Levobupivacaine Hydrochloride)

Levobupivacaine works by reversibly blocking voltage‑gated sodium channels on peripheral nerve membranes. This blockade prevents the influx of sodium ions required for depolarisation, thereby inhibiting the initiation and propagation of nerve impulses and resulting in loss of sensation in the targeted region.

The specific dose of Levobupivacaine Fresenius Kabi Deutschland is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the intended procedure. Only a qualified healthcare professional should set the dosage and administration parameters.

Safety data for levobupivacaine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use during pregnancy or while breastfeeding should only occur when clearly indicated and after a risk‑benefit assessment by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine and offers a similar duration of action with a lower risk of cardiotoxicity and central nervous system toxicity. Both agents provide effective epidural anesthesia, but levobupivacaine is often preferred when a safer cardiac profile is desired.

Levobupivacaine Fresenius Kabi Deutschland should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light, moisture, and extreme temperatures. Do not freeze the product, and ensure the vial is kept sealed until use.

The medication is administered by a qualified anesthesiologist via epidural injection. The solution is injected into the epidural space using a sterile technique, with the dose and rate carefully controlled to achieve the desired level of sensory block while monitoring the patient’s vital signs.

Serious risks include cardiac arrhythmias, severe hypotension, central nervous system toxicity such as seizures, and rare allergic reactions. Continuous cardiovascular monitoring and readiness to manage these events are essential during and after epidural administration.

Levobupivacaine should be avoided in patients with known hypersensitivity to amide‑type local anesthetics, those with severe cardiac conduction disorders, or individuals with significant hepatic impairment where drug clearance may be compromised. The decision must be made by a qualified healthcare professional.